Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice

Journal of Virology

Volumn 81, Issue 21, 2007, Pages 11840-11849

  Lin, Jianping ^a   Zhi, Yan ^a   Mays, Lauren ^a   Wilson, James M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TRL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; GAG PROTEIN; GAMMA INTERFERON; INTERLEUKIN 2; PARVOVIRUS VECTOR; TUMOR NECROSIS FACTOR ALPHA; VIRUS VACCINE;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; EFFECTOR CELL; GENE THERAPY; GENETIC CODE; MEMORY CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS TYPING;

AIDS VACCINES; ANIMALS; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DEPENDOVIRUS; GENE PRODUCTS, GAG; GENETIC VECTORS; HIV INFECTIONS; HIV-1; INTERLEUKIN-2; LIVER; LUNG; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TUMOR NECROSIS FACTOR-ALPHA;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 35448969405     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01253-07     Document Type: Article

References (44)

1. Atchison, R. W., B. C. Casto, and W. M. Hammon. 1965. Adenovirus-associated defective virus particles. Science 149:754- 756.
2. + T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J. Immunol. 175:4686-4696.
3. Bantel-Schaal, U., H. Delius, R. Schmidt, and H. zur Hausen. 1999. Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses. J. Virol. 73:939-947.
4. Bantel-Schaal, U., and H. zur Hausen. 1984. Characterization of the DNA of a defective human parvovirus isolated from a genital site. Virology 134:52-63.
5. Beattie, T., S. Rowland-Jones, and R. Kaul. 2002. HIV-1 and AIDS: what are protective immune responses? J. HIV Ther. 7:35-39.
6. + T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood 110:1132-1140.
7. Casimiro, D. R., A. Tang, L. Chen, T. M. Fu, R. K. Evans, M. E. Davies, D. C. Freed, W. Hurni, J. M. Aste-Amezaga, L. Guan, R. Long, L. Huang, V. Harris, D. K. Nawrocki, H. Mach, R. D. Troutman, L. A. Isopi, K. K. Murthy, K. Rice, K. A. Wilson, D. B. Volkin, E. A. Emini, and J. W. Shiver. 2003. Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77:7663-7668.
8. Chen, J., Q. Wu, P. Yang, H. C. Hsu, and J. D. Mountz. 2006. Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF. IX gene therapy. Mol. Ther. 13:260-269.
9. + T-cell anergy and deletion by in vivo viral gene transfer. Blood 104:969-977.
10. During, M. J., C. W. Symes, P. A. Lawlor, J. Lin, J. Dunning, H. L. Fitzsimons, D. Poulsen, P. Leone, R. Xu, B. L. Dicker, J. Lipski, and D. Young. 2000. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 287:1453-1460.
11. Farina, S. F., G. P. Gao, Z. Q. Xiang, J. J. Rux, R. M. Burnett, M. R. Alvira, J. Marsh, H. C. Ertl, and J. M. Wilson. 2001. A replication-defective vector based on a chimpanzee adenovirus. J. Virol. 75:11603-11613.
12. Gao, G., M. R. Alvira, S. Somanathan, Y. Lu, L. H. Vandenberghe, J. J. Rux, R. Calcedo, J. Sanmiguel, Z. Abbas, and J. M. Wilson. 2003. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc. Natl. Acad. Sci. USA 100:6081-6086.
13. Gao, G., L. H. Vandenberghe, M. R. Alvira, Y. Lu, R. Calcedo, X. Zhou, and J. M. Wilson. 2004. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78:6381-6388.
14. Gao, G. P., M. R. Alvira, L. Wang, R. Calcedo, J. Johnston, and J. M. Wilson. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA 99:11854-11859.
15. Garber, D. A., and M. B. Feinberg. 2003. AIDS vaccine development: the long and winding road. AIDS Rev. 5:131-139.
16. Georg-Fries, B., S. Biederlack, J. Wolf, and H. zur Hausen. 1984. Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology 134:64-71.
17. Hoggan, M. D., N. R. Blacklow, and W. P. Rowe. 1966. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc. Natl. Acad. Sci. USA 55:1467-1474.
18. Irwin, S. M., A. A. Izzo, S. W. Dow, Y. A. Skeiky, S. G. Reed, M. R. Alderson, and I. M. Orme. 2005. Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect. Immun. 73:5809-5816.
19. + T lymphocytes. Nature 421:852-856.
20. Johnson, P. R., B. C. Schnepp, M. J. Connell, D. Rohne, S. Robinson, G. R. Krivulka, C. I. Lord, R. Zinn, D. C. Montefiori, N. L. Letvin, and K. R. Clark. 2005. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J. Virol. 79:955-965.
21. Liu, D. W., Y. P. Tsao, J. T. Kung, Y. A. Ding, H. K. Sytwu, X. Xiao, and S. L. Chen. 2000. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J. Virol. 74:2888-2894.
22. Manning, W. C., X. Paliard, S. Zhou, M. Pat Bland, A. Y. Lee, K. Hong, C. M. Walker, J. A. Escobedo, and V. Dwarki. 1997. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J. Virol. 71:7960-7962.
23. Mata, M., P. J. Travers, Q. Liu, F. R. Frankel, and Y. Paterson. 1998. The MHC class I-restricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D. J. Immunol. 161:2985-2993.
24. McMichael, A. J., and T. Hanke. 2003. HIV vaccines 1983-2003. Nat. Med. 9:874-880.
25. Melnick, J. L., H. D. Mayor, K. O. Smith, and F. Rapp. 1965. Association of 20 millimicron particles with adenoviruses. J. Bacteriol. 90:271-274.
26. Mingozzi, F., Y. L. Liu, E. Dobrzynski, A. Kaufhold, J. H. Liu, Y. Wang, V. R. Arruda, K. A. High, and R. W. Herzog. 2003. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin, Investig. 111:1347-1356.
27. Opie, S. R., K. H. Warrington, Jr., M. Agbandje-McKenna, S. Zolotukhin, and N. Muzyczka. 2003. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77:6995-7006.
28. Rutledge, E. A., C. L. Halbert, and D. W. Russell. 1998. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72:309-319.
29. Sarukhan, A., C. Soudais, O. Danes, and K. Jooss. 2001. Factors influencing cross-presentation of non-self antigens expressed from recombinant adeno-associated virus vectors. J. Gene Med. 3:260-270.
30. Shedlock, D. J., and H. Shen. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337-339.
31. Shiver, J. W., and E. A. Emini. 2004. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55:355-372.
32. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, L. Huang, V. A. Harris, R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V. Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins, G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A. Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331-335.
33. Snyder, R. O., S. K. Spratt, C. Lagarde, D. Bohl, B. Kaspar, B. Sloan, L. K. Cohen, and O. Danos. 1997. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum. Gene Ther. 8:1891-1900.
34. Srivastava, I. K., J. B. Ulmer, and S. W. Barnett. 2004. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design. Expert Rev. Vaccines 3:S33-S52.
35. Vinner, L., E. G. Wee, S. Patel, S. Corbet, G. P. Gao, C. Nielsen, J. M. Wilson, H. C. Ertl, T. Hanke, and A. Fomsgaard. 2003. Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost. J. Gen. Virol. 84:203-213.
36. Wang, L., R. Calcedo, T. C. Nichols, D. A. Bellinger, A. Dillow, I. M. Verma, and J. M. Wilson. 2005. Sustained correction of disease in naïve and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood 105:3079-3086.
37. Wang, L., E. Dobrzynski, A. Schlachterman, O. Cao, and R. W. Herzog. 2005. Systemic protein delivery by muscle-gene transfer is limited by a local immune response. Blood 105:4226-4234.
38. Wherry, E. J., J. N. Blattman, K. Murali-Krishna, R. van der Most, and R. Ahmed. 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77:4911-4927.
39. Xin, K. Q., H. Mizukami, M. Urabe, Y. Toda, K. Shinoda, A. Yoshida, K. Oomura, Y. Kojima, M. Ichino, D. Klinman, K. Ozawa, and K. Okuda. 2006. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. J. Virol. 80:11899-11910.
40. Xin, K. Q., T. Ooki, H. Mizukami, K. Hamajima, K. Okudela, K. Hashimoto, Y. Kojima, N. Jounai, Y. Kumamoto, S. Sasaki, D. Klinman, K. Ozawa, and K. Okuda. 2002. Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. Hum. Gene Ther. 13:1571-1581.
41. Xin, K. Q., M. Urabe, J. Yang, K. Nomiyama, H. Mizukami, K. Hamajima, H. Nomiyama, T. Saito, M. Imai, J. Monahan, K. Okuda, and K. Ozawa. 2001. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum. Gene Ther. 12:1047-1061.
42. Zaiss, A. K., Q. Liu, G. P. Bowen, N. C. Wong, J. S. Bartlett, and D. A. Muruve. 2002. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J. Virol. 76:4580-4590.
43. Zaiss, A. K., and D. A. Muruve. 2005. Immune responses to adeno-associated virus vectors. Curr. Gene Ther. 5:323-331.
44. Zhu, J., X. Huang, and Y. Yang. 2007. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J. Virol. 81:3170-3180.